You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023146026
Dec 202342010
Jan 20244904
Feb 202436011
Mar 202488021
Apr 202470010
May 20246809
Jun 20247805
Jul 202494017
Aug 202440018
Sep 20247809
Oct 202442019
Nov 202440014
Dec 202478022
Jan 202546017
Feb 202518016
Mar 20250033
Apr 2025005
May 20250010
Jun 20250010
Total10130286